ABT vs SDHC · P/E 25, rev $44.33B vs P/E 14, rev $975.5M
Abbott Laboratories (ABT) versus Smith Douglas Homes Corp. (SDHC) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Smith Douglas Homes Corp. (SDHC) is a real estate - development company listed on NYSE.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported SDHC revenue for 2024-12-31 was $975.5M. Net income was $111.8M. Revenue was up 27.6% from 2023-12-31 to 2024-12-31. SDHC currently screens at market cap $110.6M and trailing P/E 13.9.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. SDHC currently screens at market cap $110.6M and trailing P/E 13.9.
Not investment advice. Open the ABT and SDHC stock pages for the full models.
Not investment advice.